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OBJECTIVES The goal of this research was to study the effect of planned angiography on late clinical
outcome after percutaneous coronary intervention.
BACKGROUND It is still largely unknown whether planned follow-up angiography after coronary angioplasty
influences late outcome.
METHODS Randomization assigned 527 patients to clinical follow-up alone and 531 to clinical and
six-month angiographic follow-up. The effect of planned angiography on clinical outcome at
one and three years after coronary angioplasty was studied.
RESULTS The two groups were well matched. At one year, more events occurred in the angiographic
group than in the clinical group: 122 (23.2%) versus 88 (16.7%) (p 5 0.01). While the
incidence of death or myocardial infarction (MI) was similar at one year, the revascularization
rate was higher in the angiographic group: 113 (21.3%) versus 67 (12.7%) (relative risk 5 1.7,
95% confidence interval: 1.3 to 2.3, p 5 0.0003). At three years, still more events had
occurred in the angiographic group (146 [34.5%] vs. 114 [26.3%], p 5 0.03). More
reinterventions did not improve late survival. However, there was a nonsignificant reduction
in MI (7 [1.3%] vs. 13 [2.5%], p 5 NS) and a significant improvement in functional class at
the end of follow-up (freedom from angina 81% vs. 74%, p 5 0.03). The effect of follow-up
angiography on the reintervention rate was similar for stented and nonstented patients.
CONCLUSIONS Planned follow-up angiography to evaluate the late results of coronary intervention led to a
1.7 times higher reintervention rate. This effect was similar for stented and nonstented
patients. More reinterventions did not improve survival but tended to reduce the incidence of
MI and led to a significantly better functional class at follow-up. (J Am Coll Cardiol 2001;
38:1061–9) © 2001 by the American College of Cardiology
In daily practice, late results of percutaneous coronary
intervention (PCI) are usually evaluated on the basis of
cardiac events and the recurrence of angina pectoris.
Follow-up angiography is mostly restricted to a subgroup of
symptomatic patients. In the setting of a clinical trial,
however, planned follow-up angiography is often used to
assess late angioplasty results. Yet the effect of performing
routine follow-up angiography on late clinical outcome is
still largely unknown. This question was addressed in the
BElgium NEtherlands STENT II study (Benestent-II [1]).
Patients were randomized to stent implantation or balloon
angioplasty, and there was a subrandomization to clinical
follow-up alone or to both clinical and angiographic follow-
up. It was found that follow-up angiography led to more
reinterventions. Particularly, patients assigned to balloon
angioplasty and to follow-up angiography had a strikingly
higher reintervention rate. The investigators suggested that
knowledge about the received treatment, stent or balloon,
probably influenced the treating physician’s post-
angioplasty management (1). The Balloon Angioplasty and
Anticoagulation Study (BAAS) evaluated the effect of
pre-treatment with coumarins on early and one-year events
in nonselected patients (2). Also in BAAS, a subrandom-
ization to planned six-month follow-up angiography was
used to study its effect on patient management and out-
come. In contrast with Benestent-II, BAAS patients were
not randomized to balloon angioplasty or stenting. There-
fore, BAAS allows evaluation of the effect of routine
follow-up angiography in a patient population closely re-
sembling daily practice.
METHODS
Patients and procedure. From March 1996 to November
1997, all patients with symptomatic coronary artery disease
referred by seven participating hospitals to our department
(performing 2,000 procedures/year) for PCI were candi-
dates for enrollment. Patients were randomized to aspirin
alone or to aspirin plus coumarin treatment as previously
described (2). Patients with an acute myocardial infarction
(MI) with current use of oral anticoagulants, contraindica-
tions to coumarins or aspirin or a bypass graft lesion were
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excluded. Study medication was continued for at least six
months. Stents were used for bailout situations and subop-
timal results (provisional stenting), based on visual assess-
ment only. Ticlopidine became available in the Netherlands
during the trial period. Since then, when a stent was placed,
it was left to the discretion of the operator whether to start
ticlopidine (loading dose 500 mg followed by 250 mg twice
a day for four weeks) or to continue coumarins. When
ticlopidine was given to patients randomized to coumarins,
the oral anticoagulants were discontinued. There was a 1:1
subrandomization to clinical follow-up alone or to both
clinical and angiographic follow-up. The study was carried
out according to the principles of the Declaration of
Helsinki and was approved by our institutional ethics
committee.
Follow-up. All patients were seen by their referring phy-
sicians in outpatient clinics at six weeks, three months and
one year. Clinical data and angina pectoris class were
obtained from the patients and the referring physicians. In
March 2000, all patients were additionally contacted by
telephone to study the occurrence of events and the recur-
rence of angina pectoris between one and three years of
follow-up. For those patients randomized to angiographic
follow-up, angiography was performed at six months. An-
giography was performed earlier only on request from the
referring physician when objective evidence of ischemia was
obtained. For those patients randomized to clinical
follow-up alone, the decision to perform angiography was
left to the discretion of the referring physicians. Reinter-
vention was based on angiographic restenosis and recurrent
chest pain with electrocardiographic or scintigraphic evi-
dence of ischemia. Quantitative coronary analysis was per-
formed with the Computer Measurement System (Medis,
the Netherlands) by an independent core laboratory blinded
to the assigned therapy (Heartcore, Leiden, the Nether-
lands).
Analysis. This study was undertaken to evaluate the effect
of undergoing planned six-month follow-up angiography
and the subsequent knowledge of the atherosclerotic status
on the performance of revascularization and the occurrence
of late events. The analysis was performed on an intention-
to-treat basis. We used a policy of provisional stenting.
Thus, many stents were placed in bailout situations, which
were associated with the occurrence of events. Therefore,
for the comparison of the late effect of planned follow-up
angiography in stented versus nonstented patients, the early
procedure-related events were excluded from this analysis.
Definitions and end points. The primary end point
was the composite of death, MI and revascularization at one
year. The same end point was evaluated at three years
of follow-up. Revascularization included coronary angio-
plasty or coronary artery bypass surgery (CABG) for resten-
osis and for new lesions. Events were reviewed by a safety
committee blinded to study medication and mode of
follow-up assignment. Definitions of end points were de-
scribed previously (2).
Statistical analysis. The two groups were compared using
the t test for continuous variables and the chi-square test
or, when appropriate, Fisher exact test for discrete variables.
Discrete variables were compared in terms of relative risks
(RR) with 95% confidence intervals (CI). Event-free sur-
vival was calculated by means of the Kaplan-Meier method.
Differences in survival times were assessed by the log-rank
test. A p value ,0.05 was considered significant. Multivar-
iate Cox proportional hazard regression was used to study
predictors for undergoing reintervention during follow-up
in the stented and nonstented group.
RESULTS
Patient characteristics. In BAAS, 1,028 patients were
randomized to aspirin alone or to aspirin plus coumarins.
The clinical and angiographic baseline characteristics were
described previously and were well-matched (2). Statisti-
cally, the clinical (Table 1) and angiographic baseline (Table
2) characteristics of the 527 patients in the clinical
follow-up group and of the 531 patients in the angiographic
follow-up group did not differ significantly. Additionally,
the percentages of patients with multivessel intervention
(1.43 vs. 1.46 interventions per patient, p 5 NS) were
similar in the two groups. One hundred and ninety-eight
patients (35.9%) in the clinical follow-up group and 178
patients (33.5%) in the angiographic follow-up group re-
ceived one or more stents (p 5 NS). The clinical baseline
characteristics of the stented and nonstented patients did
not differ significantly (data not shown). However, in the
stented group, more proximal left anterior descending
lesions (19.3% vs. 11.4%) and less total occlusions (4.9% vs.
10.3%) were treated than in the balloon-treated group.
Patients were followed for a mean of 29.5 6 7.0 months.
Clinical versus angiographic follow-up. Of the 531 pa-
tients randomized to follow-up angiography, 51 patients
(9.6%) did not undergo angiography for various reasons:
failed angioplasty (6 patients), subacute stent thrombosis
(6 patients), death (6 patients), CABG based on the
pre-angioplasty angiogram (3 patients), administrative error
(2 patients), groin complication during index angioplasty
(9 patients) and consent withdrawn (21 patients). These
51 patients without angiographic follow-up did not differ
significantly from the 480 patients with angiographic
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follow-up with respect to baseline characteristics or event
rates (data not shown). Of 528 patients randomized to
clinical follow-up alone, 134 patients (25.3%) underwent
angiography during follow-up. Of these, angiography was
performed in 27.4% of the stented patients, compared with
24.2% of the nonstented patients (p 5 0.70).
At one year, more events occurred in the angiographic
group than in the clinical group: 122 (23.2%) vs. 88 (16.7%),
p 5 0.01 (Fig. 1). The incidence of death or MI at one year
was similar. The difference was, therefore, due to a higher
target lesion reintervention rate in the angiographic group:
102 (19.2%) vs. 61 (11.6%) (RR 5 1.7, 95% CI: 1.2 to 2.3,
p 5 0.001) (Fig. 2 and Table 3). The higher reintervention
rate concurred with more patients being asymptomatic at six
months in the angiographic group (76.9%) compared with
those in the clinical group (71%, p 5 0.03).
At three years, there were 146 events (34.5%) in the
angiographic group and 114 (26.3%) in the clinical group
(p 5 0.03) (Fig. 1). Again, the difference was mainly due to
more reinterventions in the angiographic group. More
reinterventions did not improve survival (Fig. 3). However,
there was a nonsignificant reduction in MIs after the first
year in the angiographic group (7 [1.3%] vs. 13 [2.5%], p 5
NS). Most of these late MIs occurred in the last year of
follow-up. At three years, the functional class was signifi-
cantly better in the angiographic group; 81% of the patients
were free from angina pectoris versus 74% in the clinical
group (p 5 0.03) (Table 4).
Stent versus balloon. There was no difference in event
rates between the group treated with a stent and the group
treated with a balloon alone, whether in the clinical (Fig. 4)
or angiographic follow-up group (Fig. 5). Thus, for patients
treated with a balloon alone (Fig. 6) and for stented patients
(Fig. 7), planned follow-up angiography led to an increased
revascularization rate. The effect of planned angiography on
the performance of revascularizations was, however, more
pronounced in the balloon group (Fig. 5). Because the
baseline angiographic characteristics differed in the stented
and nonstented group with respect to the number of
proximal left anterior descending lesions and total occlu-
sions, multivariate analysis was performed. None of the
baseline characteristics was shown to be a predictor for
undergoing revascularization during follow-up. In the clin-
ical follow-up group, the reintervention rate was similar for
stented and nonstented patients (11.0% vs. 10.3%, p 5 NS).
DISCUSSION
For patients undergoing coronary intervention, there is still
controversy about the optimal means of evaluating the late
success of the procedure. Follow-up angiography is the best
method for detecting restenosis and is, therefore, used in
most clinical trials to evaluate the effect of new drugs or
devices. But is it also in the interest of the patients to
perform routine follow-up angiography in all patients?
Follow-up angiography may lead to unnecessary reinterven-
tions in asymptomatic patients. On the other hand, it may
detect symptomatic patients with restenosis who would
otherwise have escaped reintervention. It is, therefore,
essential to know whether a policy of performing routine
follow-up angiography prevents deaths or MIs and whether
it reduces angina pectoris.
In the Benestent-II trial, patients were randomly assigned
Table 1. Clinical Characteristics of the Patients
Clinical
Follow-Up
Group
(n 5 527)
Angiographic
Follow-Up
Group
(n 5 531)
Age, yr 60.1 (9.6) 60.1 (10.1)
Male gender (%) 76.3 78.7
Risk factors (%)
Diabetes 8.9 9.4
Hypertension 19.0 23.4
Total cholesterol (.5 mmol/l) 70.1 73.2
Cholesterol-lowering therapy 30.9 27.9
Smoking in preceding half year 28.7 33.7
Clinical features (%)
Previous MI 40.4 37.5
Previous angioplasty 15.3 14.6
Previous stroke 2.5 1.5
Angina class (CCS)
I 1.9 1.3
II 30.9 29.0
III 42.9 47.5
IV 24.3 22.2
IV and ST-T changes 12.0 11.5
No. of diseased vessels (%)
1 68.1 66.7
2 29.5 31.2
3 2.3 2.1
Ejection fraction ,50% (%) 17.2 18.2
Values are mean (SD) or percentages. P 5 NS for all comparisons.
CCS 5 Canadian Cardiovascular Society classification.
Table 2. Angiographic Characteristics of the Treated Lesions
Clinical
Follow-Up
(n 5 754)
Angiographic
Follow-Up
(n 5 775)
Target vessel (%)
Left anterior descending 48.1 44.5
Left circumflex 21.8 23.5
Right coronary artery 30.0 31.7
Left main coronary artery 0.1 0.3
Restenotic lesion (%) 4.5 7.3
Ostial location of lesion (%) 14.8 14.8
Bifurcated lesion (%) 8.8 8.0
Moderate or severe calcification (%) 22.9 24.1
Angulation .45° (%) 20.8 21.2
Eccentric lesion (%) 69.8 65.6
Occluded lesion (%) 9.6 8.0
Lesion length (mm)
.10 mm, (%)
11.7 (6.3)
64.4
12.0 (6.2)
68.1
Stenosis (%) of luminal diameter 80.2 (12.4) 79.8 (12.3)
Balloon size (mm) 3.06 (0.47) 3.06 (0.43)
Maximal inflation pressure (atm) 12 (3.2) 12 (3.3)
Number of vessels treated per patient 1.43 1.46
Stented lesions (%) 29.1 29.2
Values are mean (SD) or percentages. P 5 NS for all comparisons.
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Figure 1. Survival free from death, myocardial infarction (MI) and reintervention for patients randomized to clinical follow-up versus angiographic
follow-up.
Figure 2. Freedom from revascularization for patients randomized to clinical follow-up versus angiographic follow-up.
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to stenting or balloon angioplasty. Furthermore, it used the
unique setting of subrandomization to angiographic
follow-up to study the effect on patient management and
outcome. It was shown that planned follow-up angiography
led to more reinterventions. In addition, it was concluded
that the initial treatment, stent or balloon, had a major
influence on the reintervention rate. In the stent group, the
patients with angiographic follow-up underwent 2.5 times
more reinterventions than those with clinical follow-up
alone. However, in the balloon group, this ratio was only
1.5. It was concluded that receiving a stent could have
reassured the treating physician, resulting in not performing
ischemia detection and/or follow-up angiography in case of
the recurrence of symptoms. On the other hand, the known
higher restenosis rate after balloon angioplasty could have
lowered the threshold for follow-up angiography and sub-
sequent stent implantation (1).
The present BAAS trial confirms that planned follow-up
angiography leads to more reinterventions. However, in
contrast with Benestent-II, the effect of follow-up angiog-
raphy in BAAS was similar for stented and nonstented
patients. In particular, the percentage of patients undergo-
ing angiography in the clinical follow-up group of BAAS
was similar for stented and nonstented patients. Thus, the
BAAS trial could not confirm the conclusions of
Benestent-II that receiving a stent could have reassured the
treating physician or that the known higher restenosis rate
after balloon angioplasty could have lowered the threshold
for follow-up angiography. The BAAS data suggest that the
difference between a stented and a balloon-treated lesion
occurs after the follow-up angiogram is made. We could
find an only slightly higher reintervention rate in the
balloon-treated patients in the angiographic follow-up
group (Fig. 5). We speculate that this difference is due to
reluctance to redilate in-stent restenosis knowing the high
recurrence rates (3). Thus, the outcome of a restenotic lesion
that is subsequently stented is presumed to be better than
Figure 3. Survival for patients randomized to clinical follow-up versus angiographic follow-up.
Table 3. One-Year Event Rate
Angiographic
Follow-Up
(n 5 531)
Clinical
Follow-Up
(n 5 527) p Value
Death 6 (1.1%) 6 (1.1%) 1.0
MI 17 (3.2%) 21 (4.0%) 0.5
Death or MI 20 (3.8%) 23 (4.4%) 0.6
Revascularizations 113 (21.3%) 67 (12.7%) 0.0003
TLR 102 (19.2%) 61 (11.6%) 0.001
MI 5 myocardial infarction; TLR 5 target lesion reintervention.
Table 4. Angina Pectoris Between Six Months and One Year
Angiographic
Follow-Up
(n 5 502)
Clinical
Follow-Up
(n 5 508) p Value
Asymptomatic 373 (74.0%) 412 (81.1%)
Angina pectoris 84 (17.0%) 62 (12.2%)
Unstable angina 45 (9.0%) 34 (6.7%) 0.03
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that of an in-stent restenosis that is redilated. This may be
the reason why restenosis after balloon angioplasty was
more frequently treated than in-stent restenosis. We must,
however, consider the fact that BAAS patients were not
randomized to undergo stenting. Nevertheless, none of the
differences in baseline characteristics between the stented
and nonstented patients was a predictor for undergoing
revascularization during follow-up. Therefore, cautious
comparisons between the two groups can be made.
Planned follow-up angiography and mortality. A further
question in relation to the effect of follow-up angiography is
whether the knowledge on the atherosclerotic status and the
following reinterventions are beneficial or harmful to the
patient. Rupprecht et al. (4) studied 400 patients who
underwent successful coronary angioplasty and were advised
to undergo a six-month follow-up angiogram. Of these, 85
patients did not undergo follow-up angiography. The study
showed a 2.5 times increased revascularization rate in the
patients who underwent follow-up angiography. Coronary
artery bypass surgery and MI occurred at a similar rate in the
two groups. However, the absence of a six-month angio-
graphic follow-up was an independent predictor of death
associated with a 2.7 times higher mortality rate during the
10-year follow-up period (cardiac death 16/315 [5%] vs.
16/85 [16%]). It was concluded that the survival advantage
of patients with follow-up angiography was related to the
significantly higher rate of repeat angioplasties in this group.
Therefore, their advice was that routine follow-up angiog-
raphy after successful angioplasty should be strongly con-
sidered (4).
In BAAS and Benestent-II, there was no effect of
follow-up angiography on mortality. It might be that the
follow-up in these two studies was too short to detect an
effect on mortality. On the other hand, in the study by
Rupprecht et al. (4), the survival curves diverted after one
year, whereas there was no divergence even after three years
in BAAS. Furthermore, the study by Rupprecht et al. (4)
was retrospective, which might have led to a bias, as
asymptomatic patients are less likely to undergo follow-up
angiography (5). More importantly, as Rupprecht et al. (4)
rightfully suggested, the patients who are willing to undergo
follow-up angiography might be more compliant with a
healthier life style. In addition, these patients might receive
better medical treatment based on knowledge about the
atherosclerotic status of the patient, which could affect late
outcome. Thus, in the study by Rupprecht et al. (4),
follow-up angiography might have led to better secondary
prevention and, therefore, less progression, which is sug-
gested by the fact that the main difference in survival occurs
only six years post-intervention, while the majority of repeat
angioplasties were performed at the time of the angio-
graphic follow-up (4).
Figure 4. Survival free from death, myocardial infarction (MI) and reintervention for patients randomized to clinical follow-up alone (stented vs. nonstented
patients).
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Figure 5. Survival free from death, myocardial infarction (MI) and reintervention for patients randomized to angiographic follow-up (stented vs. nonstented
patients).
Figure 6. Freedom from reintervention for nonstented patients (clinical vs. angiographic follow-up).
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Planned follow-up angiography and MI. In BAAS, the
patients with follow-up angiography had 50% fewer late
MIs. For the most part, these MIs occurred in the third year
of follow-up; therefore, we do not think that the lower
incidence was caused solely by the increased number of
reinterventions, almost all of which were performed in the
first year of follow-up. It is more probable that aggressive
secondary prevention, based on knowledge of the athero-
sclerotic status of the patient, could have been part of the
reason for fewer MIs. However, because we did not system-
atically study risk factor management during the study, we
can only speculate on the cause of the reduction of MIs.
Rupprecht et al. (4), in their explanation for the survival
advantage of patients with angiographic follow-up, sug-
gested asymptomatic restenosis or silent reocclusion to be of
greater consequence in cases of disease progression in
another vessel, because of the compromise of noninvolved
systolic function when an acute event occurs. Surprisingly,
in their study, MI was not increased in the group without
angiographic follow-up.
Planned follow-up angiography and symptoms. In
BAAS, more reinterventions led to fewer symptoms at six
months and at three years. Coronary angioplasty is known
to be more effective than medical treatment in decreasing
symptoms (6). Furthermore, patients in clinical trials always
do better than patients in the real world. With this in mind,
one can surmise that the chances of a symptomatic patient’s
not receiving the benefit from repeat revascularization
would be larger than observed in this trial. As a limitation,
we did not study the extra costs of routine follow-up
angiography and of the increased reintervention rate. On
the other hand, routine follow-up angiography could lead to
an earlier relief of symptoms, an earlier discontinuation of
anti-anginal medication in case there is no restenosis, better
risk factor management, a lower late-event rate and, very
importantly, an earlier reintegration into daily social and
working life. Therefore, our observations call for a prospec-
tive randomized trial including costs and cost-effectiveness
measurements.
Conclusions. In the nonselected patient population of
BAAS, planned follow-up angiography to evaluate the late
results of coronary angioplasty led to an increased reinter-
vention rate. This effect was similar for stented and non-
stented patients. More reinterventions did not improve
survival but tended to reduce the incidence of MIs and
significantly improved the functional class.
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